https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD

FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD

The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse rea

administrator

Related Articles